elev
intraocular
pressur
iop
primari
risk
factor
develop
glaucoma
lead
caus
irrevers
blind
worldwid
idiopath
increas
resist
aqueou
humor
drainag
trabecular
meshwork
tm
schlemm
canal
convent
outflow
pathway
caus
ocular
hypertens
precis
mechan
control
outflow
resist
tm
unclear
extracellular
matrix
ecm
turnov
thought
critic
import
maintain
healthi
iop
aberr
accumul
ecm
characterist
two
major
form
glaucoma
primari
openangl
glaucoma
corticosteroidinduc
glaucoma
current
cure
glaucoma
effect
therapi
lower
iop
unfortun
clinic
avail
iop
lower
drug
directli
target
convent
drainag
tissu
address
patholog
ecm
chang
thought
imped
drainag
turnov
ecm
tm
vigor
protein
halfliv
less
two
day
tm
cell
form
highli
dynam
actinrich
organel
call
invadosom
tm
tissu
structur
enrich
matrix
metalloproteas
mmp
act
site
focal
ecm
degrad
remodel
inhibit
addit
mmp
perfus
human
eye
model
decreas
increas
outflow
respect
demonstr
critic
role
matrix
degrad
play
regul
normal
tm
function
howev
mmp
one
import
compon
organel
contribut
complex
process
matrix
remodel
recent
extracellular
nanovesicl
call
exosom
local
invadosomelik
structur
shown
critic
cellspecif
invadosom
function
invas
migrat
cancer
cell
also
activ
turnov
ecm
exosom
releas
tm
cell
cultur
yet
function
outflow
physiolog
unknown
proteom
analysi
tm
cell
exosom
show
fibronectin
fn
abund
compon
consist
number
report
shown
exosom
bind
fn
use
number
method
flowcytometri
captur
exosom
immobil
fn
densiti
gradient
ultracentrifug
result
show
exosom
affin
fn
may
common
properti
exosom
share
across
number
cell
type
recent
exosom
implic
number
cellecm
interact
includ
sever
depend
exosom
fn
data
suggest
exosomebound
fn
play
import
role
cellmatrix
interact
addit
amount
fn
bound
exosom
influenc
magnitud
cellmatrix
interact
exampl
decreas
amount
exosom
fn
decreas
cell
motil
experiment
secret
fn
tm
cell
dramat
elev
upon
treatment
corticosteroid
fact
treatment
tm
cell
tissu
corticosteroid
use
identifi
first
glaucoma
gene
myoc
reliabl
model
studi
ecm
turnov
tm
control
fashion
use
corticosteroid
treatment
tm
explant
determin
whether
releas
exosom
alter
glaucomainduc
compound
found
despit
dexamethason
dex
induc
increas
fn
secret
tm
explant
releas
exosom
less
bound
fn
addit
show
tm
exosomefn
bind
depend
presenc
glycosaminoglycan
heparan
sulfat
final
found
tm
exosom
enrich
known
heparinheparan
sulfat
bind
protein
annexin
dex
treatment
tm
explant
significantli
reduc
amount
annexin
per
exosom
find
first
demonstr
drug
caus
ecm
accumul
tm
ocular
hypertens
glaucoma
human
anim
model
alter
exosom
cargo
properti
way
account
observ
ocular
phenotyp
deidentifi
human
donor
whole
globe
corneal
rim
follow
corneal
button
remov
transplant
obtain
donor
gave
consent
research
miracl
sight
winstonsalem
nc
trabecular
meshwork
isol
use
blunt
dissect
techniqu
experi
involv
dexamethason
treatment
anterior
portion
eye
tissu
bisect
random
orient
yield
two
equal
portion
prior
tm
remov
portion
tm
explant
tissu
place
one
well
plate
low
glucos
dmem
dulbecco
modifi
eagl
medium
contain
exosomedeplet
fb
fetal
bovin
serum
uml
penicillin
streptomycin
glutamin
maintain
humidifi
air
contain
hour
prior
experiment
treatment
human
tm
cell
isol
donor
eye
use
blunt
dissect
techniqu
follow
extracellular
matrix
digest
protocol
cell
stain
character
previous
describ
follow
initi
hour
cultur
period
explant
wash
dpb
dulbecco
phosphat
buffer
salin
fresh
cultur
media
contain
vehicl
ethanol
v
v
dexamethason
ad
explant
cultur
hour
humidifi
air
contain
afterward
media
collect
store
prior
exosom
purif
tm
explant
blot
dri
weigh
frozen
three
method
exosom
isol
use
studi
major
experi
exosom
isol
precipit
follow
condit
media
spun
g
clear
supernat
transfer
clean
tube
precipit
solut
nacl
dpb
ad
clear
supernat
v
v
final
mix
repeat
invers
left
overnight
next
day
tube
centrifug
g
pellet
exosom
supernat
care
remov
tube
centrifug
g
remain
supernat
remov
pellet
exosom
resuspend
dpb
analysi
experi
involv
addit
fb
fn
condit
media
heparanas
digest
exosom
prepar
serial
ultracentrifug
follow
condit
media
centrifug
g
min
pellet
debri
clear
supernat
transfer
fresh
ultracentrifug
tube
experi
purifi
human
plasma
fibronectin
sigmaaldrich
exosomedeplet
fb
atlanta
biolog
lawrencevil
ga
fb
spun
overnight
g
ad
clear
supernat
final
concentr
v
v
respect
clear
supernat
spun
g
beckman
rotor
result
supernat
remov
transfer
anoth
ultracentrifug
tube
centrifug
g
rotor
next
supernat
discard
result
pellet
either
resuspend
dpb
directli
use
subsequ
centrifug
experi
involv
digest
heparan
sulfat
dpb
heparanas
ii
final
sigmaaldrich
ad
pellet
incub
prior
subsequ
centrifug
final
resuspend
pellet
centrifug
g
rotor
supernat
care
remov
pipett
tube
wall
wipe
clean
pellet
resuspend
bme
experi
determin
vesicl
densiti
condit
media
cm
centrifug
g
clear
supernat
concentr
use
mwco
pe
spinx
uf
concentr
corn
follow
manufactur
instruct
concentr
cm
mix
optiprep
sigmaaldrich
final
concentr
place
bottom
ultracentrifug
tube
thirti
optiprep
solut
care
layer
top
solut
centrifug
g
fraction
collect
use
pipett
weigh
determin
densiti
vesicl
diamet
concentr
determin
use
nanoparticl
track
analysi
nta
zetaview
laser
particl
metrix
meerbusch
germani
calibr
polystyren
bead
analysi
sampl
dilut
dpb
measur
posit
within
imag
chamber
use
determin
sampl
vesicl
size
concentr
exosom
sampl
solubil
laemmli
buffer
load
onto
sdspage
gel
equal
volum
equal
particl
number
separ
electrophoret
transfer
nitrocellulos
membran
block
fatfre
milkwat
room
temp
rock
platform
block
solut
exchang
primari
antibodi
solut
antibodi
dilut
fatfre
milktbst
incub
rock
platform
room
temperatur
overnight
primari
antibodi
use
follow
antifn
santa
cruz
antiannexin
bd
transduct
laboratori
antiannexin
abcam
lactadherin
santa
cruz
myocilin
custom
polyclon
primari
antibodi
remov
blot
wash
time
minut
tbst
antibodi
solut
contain
secondari
hrpconjug
antibodi
goat
antimous
hrp
goat
antirabbit
hrp
jackson
immunoresearch
west
grove
pa
ad
incub
room
temperatur
rock
blot
wash
time
min
tbst
develop
use
chemiluminesc
reagent
hyglo
denvil
scientif
south
plainfield
nj
xray
film
genese
scientif
san
diego
ca
tm
cell
condit
media
collect
serumfre
centrifug
g
split
equal
seven
way
purifi
heparan
sulfat
sigmaaldrich
ad
increas
concentr
media
tube
contain
condit
sulfat
incub
rocker
room
temperatur
exosom
isol
precipit
describ
result
exosom
pellet
resuspend
pb
nitrocellulos
membran
wet
tb
place
dotblot
apparatu
biorad
membran
wash
per
manufactur
instruct
exosom
sampl
ad
well
apparatu
incub
low
vacuum
follow
full
vacuum
wash
time
tb
membran
remov
dri
next
membran
rewet
tb
block
fatfre
milkwat
room
temp
rock
platform
block
solut
exchang
antifn
antibodi
santa
cruz
solut
antibodi
dilut
fatfre
milktbst
incub
rock
platform
room
temperatur
primari
antibodi
remov
blot
wash
time
tbst
secondari
antibodi
solut
goat
antimous
hrp
jackson
immunoresearch
ad
incub
room
temperatur
rock
membran
wash
time
tbst
develop
use
chemiluminesc
reagent
hyglo
xray
film
genese
scientif
serumfre
condit
media
human
tm
cell
collect
exosom
prepar
describ
exosom
resuspend
dpb
centrifug
pellet
insolubl
protein
result
supernat
incub
rotat
heparin
sepharos
fast
flow
bead
overnight
bead
wash
dpb
incub
trypsin
gold
promega
corpor
ammonium
bicarbon
overnight
digest
solut
vacuum
dri
savant
speedvac
digest
peptid
process
identifi
quantifi
lcmsm
previous
describ
xray
film
exposur
band
appear
within
dynam
rang
film
scan
canon
lide
scanner
band
intens
determin
use
nih
imagej
gel
analysi
tool
comparison
band
intens
sampl
load
equal
volum
measur
band
intens
normal
number
particl
determin
nta
per
lane
experi
equal
number
particl
load
per
lane
band
intens
directli
compar
cultur
human
tm
cell
releas
extracellular
vesicl
ev
properti
consist
exosom
howev
ev
releas
human
tm
cell
resid
intact
tissu
never
shown
address
ev
prepar
condit
media
tm
explant
dissect
human
donor
eye
result
ev
size
consist
exosom
fig
compar
type
ev
exosom
report
uniqu
enrich
tetraspanin
includ
annexin
phosphatidylserin
bind
protein
lactadherin
western
blot
show
tm
explant
deriv
ev
contain
annexin
lactadherin
fig
inset
ev
differenti
densiti
thu
ev
releas
human
tm
explant
analyz
floatat
continu
iodixanol
optiprep
densiti
gradient
gradient
fraction
collect
nanoparticl
concentr
quantifi
nanoparticl
track
analysi
major
tm
explant
ev
rang
gml
fig
densiti
consist
exosom
addit
vesicl
within
densiti
rang
size
distribut
ident
exosom
diamet
mean
nm
mode
nm
fig
inset
summari
data
demonstr
first
time
base
current
accept
criteria
exosom
produc
organotyp
cultur
model
tm
exosom
isol
number
biolog
fluid
cell
type
includ
human
tm
cell
bound
fibronectin
fn
tm
cell
secret
fibronectin
increas
secret
respons
corticosteroid
treatment
determin
whether
exosom
tm
explant
also
bind
fibronectin
whether
dex
treatment
impact
bind
split
tm
tissu
singl
donor
eye
two
equal
portion
control
known
donor
variabl
corticosteroidrespons
cultur
separ
presenc
absenc
dexamethason
dex
nm
day
western
blot
show
human
tm
explant
respond
dex
treatment
like
tm
cell
vitro
increas
fn
myocilin
myoc
secret
fig
increas
fn
secret
hypothes
dex
treatment
human
tm
explant
increas
amount
fn
bound
releas
exosom
compar
exosom
untreat
explant
six
individu
donor
tissu
test
dex
significantli
affect
mean
mode
vesicl
size
fig
slight
increas
mean
vesicl
concentr
dex
treat
sampl
chang
vari
donor
donor
signific
fig
exosom
control
dex
treat
tm
explant
analyz
fn
content
western
blot
contrari
hypothesi
despit
variabl
donor
signific
decreas
amount
fn
detect
per
exosom
fig
better
understand
chang
occur
dex
treatment
affect
fn
bind
capac
exosom
perhap
account
ecm
accumul
steroidinduc
glaucoma
investig
bind
fn
tm
exosom
vitro
exosom
prepar
serum
starv
cell
probe
fn
abund
trace
amount
fn
detect
fig
howev
tm
condit
media
serumfre
incub
fb
purifi
fn
exosom
prepar
exosom
pellet
bound
fn
sinc
neither
fb
purifi
fn
alon
pellet
ident
condit
conclud
tm
cell
exosom
releas
without
fn
capac
bind
outsid
parent
cell
recent
exosom
shown
bind
fn
via
heparan
sulfat
proteoglycan
syndecan
detect
tm
exosom
proteom
secret
heparan
sulfat
proteoglycan
perlecan
observ
test
whether
receptor
heparan
sulfat
exist
mediat
fn
bind
tm
exosom
incub
condit
media
tm
cell
monolay
increas
concentr
heparan
sulfat
isol
exosom
condit
media
probe
fn
result
show
concentrationdepend
increas
exosomebound
fn
attain
maxim
bind
statist
signific
pgml
heparan
sulfat
fig
interestingli
fnexosom
bind
biphas
first
increas
decreas
dosedepend
higher
heparan
sulfat
concentr
experi
fn
sourc
exosom
bind
fn
secret
tm
cell
serum
free
media
hr
separ
experi
basal
fn
concentr
measur
use
data
construct
doserespons
curv
allow
us
estim
valu
pgml
heparan
sulfat
given
fn
concentr
fig
test
whether
heparan
sulfat
mediat
exosomefn
bind
bacteri
heparanas
shown
remov
exosomebound
fn
fig
similar
previous
report
data
confirm
tm
exosom
releas
surfac
receptor
heparan
sulfat
mediat
bind
fn
exosom
identifi
exosom
protein
capabl
bind
heparinheparan
sulfat
purifi
exosom
human
tm
cell
exosom
lyse
sd
centrifug
remov
insolubl
protein
result
supernat
incub
heparin
sepharos
bead
bead
wash
bound
protein
digest
trypsin
identif
lcmsm
protein
identifi
biolog
replic
two
known
heparin
bind
protein
identifi
fibronectin
annexin
tabl
remain
identifi
protein
cytoskelet
known
bind
heparin
like
repres
contamin
data
demonstr
annexin
tm
exosom
like
candid
exosom
heparin
receptor
sinc
treatment
human
tm
explant
dex
decreas
fn
bound
releas
exosom
exosomefn
bind
depend
heparan
sulfat
next
test
whether
exosom
dex
treat
tm
explant
show
decreas
heparinheparan
sulfat
bind
annexin
exosom
dex
treat
human
tm
explant
significantli
lower
amount
annexin
immunoblot
compar
exosom
untreat
explant
fig
sinc
bind
fn
tm
exosom
mediat
heparinheparan
sulfat
conclud
reduct
heparinheparan
sulfat
bind
protein
like
contribut
decreas
fn
bind
exosom
dex
treat
explant
fnbound
exosom
report
mediat
number
cellmatrix
interact
includ
migrat
invas
two
process
depend
podosomesinvadopodia
ecm
digest
sinc
dex
treatment
tm
decreas
mmp
secretionact
accumul
matrix
materi
next
test
whether
dex
alter
exosom
proteas
activ
initi
studi
fail
detect
exosomespecif
mmp
activ
use
insolut
fluoresc
gelatinas
assay
howev
proteom
analysi
tm
exosom
identifi
serin
proteas
dipeptidyl
local
invadopodia
inhibit
result
reduc
invas
examin
specif
observ
exosom
releas
dex
treat
tm
explant
significantli
reduc
level
activ
compar
untreat
control
fig
reduct
activ
dex
treatment
consist
result
ecm
dysregul
accumul
tm
patient
steroid
induc
ocular
hypertens
like
primari
tm
cell
cultur
show
explant
human
trabecular
meshwork
organ
cultur
produc
exosom
dexamethason
treatment
explant
alter
tm
function
caus
glaucoma
significantli
reduc
fn
exosom
surfac
mechanist
show
tm
exosomefn
bind
depend
heparan
sulfat
significantli
two
heparinheparan
sulfat
bind
annexin
plu
peptidas
reduc
upon
treatment
explant
dex
taken
togeth
data
support
mechan
dex
neg
impact
exosomemedi
bind
ecm
homeostat
degrad
tm
cell
tm
impair
matrix
degrad
result
decreas
aqueou
humor
drainag
lead
elev
intraocular
pressur
primari
risk
factor
develop
glaucoma
support
notion
increas
ecm
accumul
common
hallmark
tm
tissu
glaucomat
patient
impair
ecm
turnov
glaucomat
tm
suggest
mechan
interact
modifi
surround
ecm
dysfunct
cell
interact
surround
matrix
sever
cellular
structur
rang
migratori
podosom
invas
invadopodia
fall
gener
categori
invadosom
structur
perform
differ
function
cell
appear
util
interconnect
process
mind
exosom
shown
perform
essenti
function
number
structur
exampl
exosom
releas
promot
format
invadopodia
exosom
also
promot
assembl
focal
adhes
control
rapid
direction
cell
migrat
later
phenomenon
due
fn
bound
exosom
surfac
may
help
match
matrix
ligand
complimentari
cell
surfac
receptor
coordin
invadosom
function
sinc
exosom
bound
fn
essenti
compon
invadosom
data
support
mechan
similar
scenario
occur
invadosom
tm
cell
thu
dexinduc
reduct
exosom
bound
fn
provid
part
explan
accumul
ecm
materi
tm
dexinduc
anim
model
ocular
hypertens
patient
steroid
induc
glaucoma
sever
receptor
mediat
fn
bind
exosom
includ
heparan
sulfat
proteoglycan
integrin
data
support
addit
mechan
fn
bind
exosom
complex
heparan
sulfat
annexin
protein
purifi
tm
exosom
found
number
protein
annexin
famili
tetraspanin
known
enrich
exosom
thought
locat
exosom
surfac
tm
exosom
detect
abund
express
hsheparinbind
annexin
idea
exosom
releas
receptor
heparinheparan
sulfat
surfac
support
recent
describ
method
exosom
purif
via
heparin
affin
column
sinc
well
known
fn
bind
heparinheparan
sulfat
propos
exosom
annexin
coordin
bind
heparinheparan
sulfat
fn
tm
exosom
present
studi
abl
alter
fn
bind
exosom
three
way
first
dex
treatment
reduc
exosom
fn
bind
parallel
reduct
exosom
annexin
reduct
tm
exosom
annexin
like
due
accumul
annexin
tm
cell
membran
follow
dex
treatment
second
show
addit
purifi
heparan
sulfat
increas
affin
tm
exosom
fn
third
remov
exosom
bound
fn
enzymat
cleav
heparan
sulfat
togeth
demonstr
tmderiv
exosom
bind
fibronectin
mechan
similar
distinctli
differ
mechan
use
myeloma
cellderiv
exosom
exact
role
exosom
cellmatrix
interact
degrad
unclear
howev
exosom
number
sourc
shown
possess
proteolyt
activ
crucial
degrad
ecm
membran
bound
detect
exosom
abl
cleav
collagen
gelatin
activ
form
mmp
activ
critic
import
maintain
outflow
facil
therefor
tm
function
unexpectedli
unabl
detect
mmp
activ
attribut
instead
tm
exosom
possess
activ
protein
serin
proteas
cleav
two
ntermin
amino
acid
protein
second
amino
acid
prolin
alanin
possibl
serin
transmembran
region
cleav
solubl
form
total
number
physiolog
substrat
unknown
propos
may
extens
includ
signal
molecul
known
affect
tm
functionoutflow
facil
bfgf
bradykinin
signal
molecul
shown
reduc
receptor
affin
efficaci
compar
fulllength
counterpart
also
shown
possess
number
extraenzymat
properti
bind
fn
mediat
viru
uptak
although
signific
exosom
unknown
local
invadopodia
affect
cell
migrationinvas
involv
cell
adhes
fn
context
reduct
exosom
activ
dex
treat
tm
explant
may
reflect
gener
dysfunct
tm
ecm
homeostasi
result
dex
treatment
data
present
first
descript
activ
tm
futur
studi
determin
role
play
tm
cell
function
outflow
facilityiop
via
enzymat
extraenzymat
properti
corticosteroid
number
patholog
effect
tm
exampl
dex
decreas
phagocyt
activ
tm
cell
increas
secret
number
ecm
compon
inhibit
tm
cell
migrat
alter
actin
cytoskeleton
interestingli
exosom
may
link
process
cell
migrat
sinc
format
invadosom
structur
depend
coordin
actin
rearrang
dexinduc
crosslink
actin
network
clan
may
inhibit
format
invadosom
thu
alter
exosom
releas
chose
use
dex
model
tm
dysfunct
lead
decreas
aqueou
humor
drainag
increas
iop
glaucoma
elev
level
cytokin
aqueou
humor
also
link
patholog
chang
tm
glaucoma
surprisingli
global
effect
tm
similar
dex
includ
format
clan
increas
secret
ecm
compon
accumul
ecm
materi
tm
sinc
exosom
local
invadopodia
promot
format
observ
increas
matrix
degrad
tm
invadosom
suggest
relationship
exosom
warrant
investig
result
focus
dexinduc
reduct
exosom
fibronectin
affin
identifi
bind
mechan
heparinheparan
sulfat
bridg
candid
heparinheparan
sulfat
bind
exosom
protein
annexin
protein
previous
identifi
highli
enrich
tm
exosom
along
two
exosom
protein
examin
annexin
data
show
dex
treatment
result
decreas
annexin
activ
tm
explant
exosom
like
effect
dex
exosom
protein
composit
limit
protein
sinc
dex
work
primarili
activ
glucocorticoid
receptor
effect
cell
physiolog
broad
futur
studi
determin
chang
exosom
protein
composit
result
exosom
properti
stem
dex
treatment
summari
data
show
first
time
human
tm
explant
releas
exosom
moreov
add
list
effect
corticosteroid
tm
show
dex
treatment
caus
chang
exosom
cargo
properti
result
connect
hallmark
chang
glaucomat
tm
tissu
ecm
accumul
role
exosom
cellmatrix
interact
suspect
connect
limit
dexinduc
chang
tm
therefor
hypothes
chang
exosom
cargo
properti
underli
mani
form
poag
futur
studi
test
hypothesi
examin
whether
model
glaucomat
tm
dysfunct
treatment
also
produc
patholog
chang
exosom
cargo
function
